On April 9, the Pan American Health Organization launched its Clinical Trial Accelerator initiative -- a regional harmonization push that pairs with Argentina's operative 62-day ANMAT cap, Brazil's RDC 997/2025 reliance queue, and Ecuador's new ARCSA framework. Plus the IGC Pharma CALMA Phase 2 win in Colombia and the ANVISA Cannabis Regulatory Framework (RDC 1,011-1,015).
Regional · Argentina · Brazil · Ecuador · Colombia
bioaccess(R) | Global Trial Accelerators(TM) | Fast-Tracking First-in-Human Trials, Anywhere
A new institutional framework is taking shape across the Americas -- one designed to make multi-country early-phase clinical research faster, less fragmented, and more coordinated than anything the region has seen before.
This week:
Take a closer look at the structural shifts reshaping first-in-human research in Latin America.
On April 9, the Pan American Health Organization launched the Clinical Trial Accelerator -- an initiative to harmonize clinical trial agreements, deploy AI-driven design tools, and support multi-country trial platforms across Latin America and the Caribbean. The initiative includes the Portal of Clinical Trials of the Americas, a centralized resource hub providing standardized guidance, regulatory tools, and harmonized documentation.
PAHO Director Dr. Jarbas Barbosa stated that the Accelerator "drives research collaboration by providing tools that range from conceptual design to AI-driven innovation, shifting the focus from reactive research to proactive, visionary solutions." The initiative builds on a 2023 regional workshop and a 2023 World Health Assembly resolution on clinical trial strengthening.
Why It Matters: For sponsors running multi-site FIH programs across two or three LATAM countries, the single most time-consuming barrier is the country-by-country negotiation of clinical trial agreements, insurance requirements, and site contracts. Standardized CTAs could shave weeks from study startup -- and PAHO is now building the institutional infrastructure to make that real.
In conjunction with the Accelerator launch, Ecuador presented new clinical trial regulations developed with PAHO technical assistance -- marking the first serious attempt at regulatory modernization for clinical research in a country that has been largely absent from the regional trial landscape. Specific regulatory text and effective dates are pending publication, but the signal is clear: Ecuador's regulatory authority (ARCSA) is positioning to become a viable option for sponsors seeking additional site diversity in the region.
Bottom Line: Ecuador's entry opens a potential eighth country option for LATAM FIH programs. For sponsors facing enrollment constraints in the traditional five-market corridor (Argentina, Brazil, Chile, Colombia, Mexico), Ecuador could provide population diversity and geographic reach that reduces single-country risk.
IGC Pharma (NYSE: IGC) expanded its Phase 2 CALMA trial for Alzheimer's agitation into Colombia by adding Grupo de Neurociencias de Antioquia (GNA) in Medellin -- a research center that holds the world's only access to carriers of the "Paisa mutation," a genetically defined population with early-onset familial Alzheimer's disease. GNA joins 23 existing sites across the U.S. and Canada. The trial has reached approximately 70% enrollment, with topline results expected by mid-2026.
Why It Matters: This expansion confirms that Colombia is not limited to device or rare disease trials. For neuroscience sponsors, the GNA cohort represents a patient population with no equivalent anywhere else -- a compelling strategic reason to include Colombia in complex therapeutic programs.
Does your company need accelerated first-in-human clinical trial results? bioaccess(R) partners with Medtech, Biopharma, and Radiopharma startups worldwide to deliver faster approvals and lower costs in Latin America.
Bring your innovations to market faster with Latin America's first-in-human trial experts.
Schedule your first-in-human trial consultation at bioaccessla.com.
ANVISA published five new resolutions (RDC 1,011 through RDC 1,015/2026) establishing an end-to-end regulatory framework for medicinal cannabis in Brazil. Most significant for clinical research: RDC 1,012 allows cultivation for research purposes with no THC limit, and RDC 1,014 creates a Regulatory Sandbox -- an experimental environment for cannabis cultivation, plant-based API production, and small-scale preparations under direct ANVISA supervision. The Sandbox is already in effect.
The broader framework also expands routes of administration (buccal, sublingual, dermatological) and broadens patient access eligibility beyond palliative care, with the commercial provisions (RDC 1,015) taking effect May 4, 2026.
What to Focus On: For sponsors developing cannabinoid-based therapeutics, Brazil now has a formally defined pathway for early-phase clinical research under ANVISA oversight -- including a Regulatory Sandbox designed for exactly this type of exploratory work. Participation will be via public call.
Argentina's three simultaneous regulatory reforms -- the 62-day FIH statutory cap (Disposicion 7516/2025), simplified device imports via the Helena digital platform (Disposicion 236/2026), and streamlined establishment licensing via Themis (Disposicion 8799/2025) -- are now fully operative. The 62-day cap introduced parallel review between ANMAT and ethics committees, aligning with ICH E6(R3).
ANMAT is expected to publish its first Q2 2026 actual timeline data, which will provide the first empirical test of whether the statutory cap translates into real-world approval speed.
Bottom Line: The regulatory architecture is in place. The next milestone is data. If ANMAT's Q2 figures confirm that 62-day approvals are achievable in practice, Argentina becomes the fastest FIH approval pathway in Latin America -- and a direct competitor to Australia and New Zealand for global sponsor attention.
---
bioaccess(R) | Fast-Tracking First-in-Human Trials, Anywhere.
Follow us on LinkedIn | Subscribe to Global Trial Accelerators(TM)
← All Global Trial Accelerators editions · Contact bioaccess®